AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

TD Cowen analyst Joseph Thome maintained a Buy rating on AnaptysBio (ANAB – Research Report) today. The company’s shares opened today at ...

H.C. Wainwright analyst Emily Bodnar downgraded AnaptysBio (ANAB) to Neutral from Buy with a $19 price target Pick the best stocks and maximize ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral. Analyst Price Forecast Suggests 257.63% Upside As of December ...

Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

The rebel leader who helped oust the Assad regime calls on countries to hand over “criminals” who fled Syria. A new caretaker prime minister warns that the country faces a dire financial ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...